Novel MCI Nomogram Developed to Assess Alzheimer's Disease Risk

Strategic Insights -

A recent study has made a significant breakthrough in predicting mild cognitive impairment (MCI) in middle-aged and elderly populations. Researchers from the Department of Chronic Disease, Chifeng Center for Disease Control and Prevention, in collaboration with international experts, have developed a novel MCI nomogram that integrates air pollution, sociodemographic, and clinical predictors to assess the risk of MCI in Chinese adults. The study aims to identify individualized risk factors for MCI, enabling targeted prevention strategies and improving the diagnosis and treatment of Alzheimer's disease.

Key Takeaways:

  • The novel MCI nomogram was developed using the 2015 CHARLS cohort of 7,702 participants, randomly split into training (n = 5,391) and validation (n = 2,311) groups.
  • Uni-variate analysis identified MCI risk factors, including age 75 years, private medical insurance, married individuals, and males.
  • Multivariate analysis in Model 2 identified 13 key factors associated with MCI, including age 75 years (OR = 5.437, 95% CI: 3.524-8.388, p < 0.001).
  • Model 2 demonstrated better discrimination, calibration, clinical utility, and accuracy compared to Model 1.
  • The validated nomogram enables individualized MCI risk stratification, supporting targeted community prevention strategies.
  • The research has significant implications for the prevention and treatment of Alzheimer's disease, particularly in middle-aged and elderly populations.
  • The study highlights the importance of incorporating environmental and sociodemographic factors into MCI risk assessment tools.

Statistics:

  • The study analyzed 7,702 participants from the 2015 CHARLS cohort.
  • The participants were randomly split into training (n = 5,391) and validation (n = 2,311) groups.
  • Model 2 demonstrated an OR of 5.437 (95% CI: 3.524-8.388, p < 0.001) for MCI risk associated with age 75 years.
  • Model 2 outperformed Model 1 in terms of discrimination (C-index, ROC), calibration, clinical utility (decision curves), and predictive performance (net reclassification improvement, NRI, and integrated discrimination improvement, IDI).

Sources:

  • Yang Yu, et al. Development and validation of a predictive nomogram for mild cognitive impairment in middle-aged and elderly populations: A multi-module analysis integrating air quality and sociodemographic factors. Journal of Alzheimer's Disease, 2025:13872877251378520.
  • Yang Yu, Dept. of Chronic Disease, Chifeng Center for Disease Control and Prevention, Chifeng, Inner Mongolia Autonomous Region, People's Republic of China.
  • Ios Press, Nieuwe Hemweg 6B, 1013 Bg Amsterdam, Netherlands (Publisher of the Journal of Alzheimer's Disease).
  • NewsRx. New Alzheimer's Disease Study Findings Recently Were Reported by Researchers at Department of Chronic Disease (Development and validation of a predictive nomogram for mild cognitive impairment in middle-aged and elderly populations: A ...). Mental Health Weekly Digest. October 20, 2025; p 86.